Patents by Inventor Susan Mary Kingsman
Susan Mary Kingsman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120213822Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: ApplicationFiled: February 21, 2012Publication date: August 23, 2012Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Patent number: 8147838Abstract: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their used in diagnosis and therapy of cancer.Type: GrantFiled: May 12, 2006Date of Patent: April 3, 2012Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, William Shingler, Susan Mary Kingsman
-
Patent number: 8133681Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: GrantFiled: March 20, 2008Date of Patent: March 13, 2012Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Patent number: 8084249Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: February 26, 2010Date of Patent: December 27, 2011Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20110065173Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: February 26, 2010Publication date: March 17, 2011Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20110052577Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: July 28, 2010Publication date: March 3, 2011Applicant: Oxford Biomedica (UK) LimitedInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7888115Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: GrantFiled: July 10, 2009Date of Patent: February 15, 2011Assignee: Oxford Biomedica (UK) LimitedInventors: Miles William Carroll, Susan Mary Kingsman, Irina Redchenko
-
Publication number: 20100158884Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.Type: ApplicationFiled: February 3, 2010Publication date: June 24, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Miles William Carroll, Susan Mary Kingsman
-
Publication number: 20100040539Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: May 15, 2008Publication date: February 18, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7635687Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: December 30, 2002Date of Patent: December 22, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Publication number: 20090291491Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.Type: ApplicationFiled: September 30, 2008Publication date: November 26, 2009Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
-
Patent number: 7531648Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: March 22, 2002Date of Patent: May 12, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20090111106Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: ApplicationFiled: July 7, 2008Publication date: April 30, 2009Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Mary Kingsman
-
Patent number: 7514546Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognizing a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: GrantFiled: April 26, 2006Date of Patent: April 7, 2009Assignee: Oxford BioMedica (UK) Ltd.Inventors: Susan Mary Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Kevin A. Myers
-
Publication number: 20090047307Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: ApplicationFiled: March 20, 2008Publication date: February 19, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Publication number: 20090017532Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: August 6, 2008Publication date: January 15, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20080131400Abstract: Provided is a method of treating motor neuron disease using a lentiviral vector system to transduce a target site, wherein the vector system is or comprises at least part of a rabies G envelope protein or a mutant, variant, homologue or fragment thereof, and a nucleotide of interest (NOI), and wherein the target site is at least part of the central nervous system.Type: ApplicationFiled: June 4, 2007Publication date: June 5, 2008Inventors: Nicholas Mazarakis, Mimoun Azzouz, Susan Mary Kingsman
-
Publication number: 20080125387Abstract: Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.Type: ApplicationFiled: February 12, 2007Publication date: May 29, 2008Inventors: Katie Mary Binley, Susan Mary Kingsman, Stuart Naylor
-
Patent number: 7303910Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.Type: GrantFiled: April 30, 2004Date of Patent: December 4, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
-
Patent number: 7198784Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.Type: GrantFiled: September 11, 2003Date of Patent: April 3, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous